Here, we present additional evidence for the prognostic relevance of MTSS1 in AML: MTSS1 was downregulated at relapse of AML, and in genetically defined intermediate and poor risk subgroups as compared to the corresponding good risk groups. This evidence concerns the gene MTSS1 and acute myeloid leukemia.